
James A Watson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/250569/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2020, 383, 2030-2040.	27.0	1,013
2	COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. PLoS Medicine, 2020, 17, e1003252.	8.4	86
3	Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1094-1099.	1.4	77
4	Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. Nature Communications, 2019, 10, 5595.	12.8	70
5	Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. Clinical Infectious Diseases, 2018, 67, 1543-1549.	5.8	52
6	Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. Clinical Infectious Diseases, 2019, 68, 1311-1319.	5.8	49
7	Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. PLoS Neglected Tropical Diseases, 2018, 12, e0006440.	3.0	45
8	Modelling primaquine-induced haemolysis in G6PD deficiency. ELife, 2017, 6, .	6.0	38
9	The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Medicine, 2019, 17, 151.	5.5	34
10	Non-adherence in non-inferiority trials: pitfalls and recommendations. BMJ, The, 2020, 370, m2215.	6.0	29
11	Approximate Models and Robust Decisions. Statistical Science, 2016, 31, .	2.8	27
12	Investigating causal pathways in severe falciparum malaria: A pooled retrospective analysis of clinical studies. PLoS Medicine, 2019, 16, e1002858.	8.4	26
13	A molecular barcode to inform the geographical origin and transmission dynamics of Plasmodium vivax malaria. PLoS Genetics, 2020, 16, e1008576.	3.5	24
14	Concomitant Bacteremia in Adults With Severe Falciparum Malaria. Clinical Infectious Diseases, 2020, 71, e465-e470.	5.8	22
15	Protective effect of Mediterranean-type glucose-6-phosphate dehydrogenase deficiency against Plasmodium vivax malaria. ELife, 2021, 10, .	6.0	22
16	Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision. ELife, 2021, 10, .	6.0	22
17	Concentration-dependent mortality of chloroquine in overdose. ELife, 2020, 9, .	6.0	21
18	Age, exposure and immunity. ELife, 2018, 7, .	6.0	20

JAMES A WATSON

#	Article	IF	CITATIONS
19	Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	17
20	Split dosing of artemisinins does not improve antimalarial therapeutic efficacy. Scientific Reports, 2017, 7, 12132.	3.3	16
21	Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	16
22	A decision-theoretic approach to the evaluation of machine learning algorithms in computational drug discovery. Bioinformatics, 2019, 35, 4656-4663.	4.1	15
23	Collider bias and the apparent protective effect of glucose-6-phosphate dehydrogenase deficiency on cerebral malaria. ELife, 2019, 8, .	6.0	15
24	Tafenoquine for the prevention of Plasmodium vivax malaria relapse. Lancet Microbe, The, 2021, 2, e175-e176.	7.3	13
25	Characterizing Blood-Stage Antimalarial Drug MIC Values <i>In Vivo</i> Using Reinfection Patterns. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	12
26	Prediction of disease severity in young children presenting with acute febrile illness in resource-limited settings: a protocol for a prospective observational study. BMJ Open, 2021, 11, e045826.	1.9	12
27	Machine learning analysis plans for randomised controlled trials: detecting treatment effect heterogeneity with strict control of type I error. Trials, 2020, 21, 156.	1.6	11
28	Stopping prereferral rectal artesunate — a grave error. BMJ Global Health, 2022, 7, e010006.	4.7	11
29	Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with Plasmodium vivax Malaria. Antimicrobial Agents and Chemotherapy, 2021, 65, e0130221.	3.2	10
30	The probability of a sequential Plasmodium vivax infection following asymptomatic Plasmodium falciparum and P. vivax infections in Myanmar, Vietnam, Cambodia, and Laos. Malaria Journal, 2019, 18, 449.	2.3	7
31	Characterizing variation of nonparametric random probability measures using the Kullback–Leibler divergence. Statistics, 2017, 51, 558-571.	0.6	5
32	A semi-supervised learning framework for quantitative structure–activity regression modelling. Bioinformatics, 2021, 37, 342-350.	4.1	5
33	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. Wellcome Open Research, 2021, 6, 71.	1.8	5
34	A cautionary note on the use of unsupervised machine learning algorithms to characterise malaria parasite population structure from genetic distance matrices. PLoS Genetics, 2020, 16, e1009037.	3.5	5
35	Methaemoglobinaemia and the radical curative efficacy of 8â€aminoquinoline antimalarials. British Journal of Clinical Pharmacology, 2022, 88, 2657-2664.	2.4	5
36	Rejoinder: Approximate Models and Robust Decisions. Statistical Science, 2016, 31, .	2.8	4

JAMES A WATSON

#	Article	IF	CITATIONS
37	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. Wellcome Open Research, 2021, 6, 71.	1.8	4
38	A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: Application to a dose-finding trial for a novel Russell's viper antivenom in Myanmar. PLoS Neglected Tropical Diseases, 2020, 14, e0008109.	3.0	4
39	Graphing and reporting heterogeneous treatment effects through reference classes. Trials, 2020, 21, 386.	1.6	3
40	Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2022, 112, 824-835.	4.7	3
41	Antimalarial Resistance Unlikely To Explain U.K. Artemether-Lumefantrine Failures. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	1
42	Time-to-death is a potential confounder in observational studies of blood transfusion in severe malaria. Lancet Haematology,the, 2021, 8, e12.	4.6	1
43	Falciparum malaria mortality in sub-Saharan Africa in the pretreatment era. Trends in Parasitology, 2021, , .	3.3	1
44	Questioning the Claimed Superiority of Malaria Parasite Ex Vivo Viability Reduction Over Observed Parasite Clearance Rate?. Journal of Infectious Diseases, 2021, 224, 738-739.	4.0	0
45	Severe malaria, Pascalian therapeutics and the US FDA. Clinical Infectious Diseases, 2022, , .	5.8	0
46	Title is missing!. , 2020, 16, e1009037.		0
47	Title is missing!. , 2020, 16, e1009037.		0
48	Title is missing!. , 2020, 16, e1009037.		0
49	Title is missing!. , 2020, 16, e1009037.		0
50	Title is missing!. , 2020, 14, e0008109.		0
51	Title is missing!. , 2020, 14, e0008109.		0
52	Title is missing!. , 2020, 14, e0008109.		0
53	Title is missing!. , 2020, 14, e0008109.		0